smart ecm
43° National congress of the italian society of pharmacology creating value through pharmacological research25 - 28 novembre 2026Torino17 crediti500,00 €

43° National congress of the italian society of pharmacology creating value through pharmacological research

Di 3P Solution Srl

25 - 28 novembre 2026

Torino

17 ore

17crediti ECM
500,00 €80 posti
In breve

Quattro giornate dedicate alle applicazioni attuali della farmacologia, dalla ricerca sui meccanismi d’azione e sullo sviluppo dei medicinali fino alla valutazione…

Riassunto a cura di Smart ECM

Info basate su dati pubblici Agenas. Smart ECM non è responsabile del corso e non ha accordi con il provider che lo organizza. Contattaci

Drugs arrive faster, and complexity grows with them

Congresso nazionale SIF (Società Italiana di Farmacologia), 4 giorni a Torino, con sessioni ECM in farmacologia sperimentale, traslazionale e clinica: metabolismo, dolore cronico, neuroscienze, malattie infiammatorie, epilessie e farmacologia di genere.

A congress of a learned society serves to showcase the activities and research of the members, to imagine and shape together the future of the discipline, and to bring together professionals with similar backgrounds to allow them to establish collaborations and exchange best practices. The Congress in Turin embraces all three of these missions.

Ample space will be given, as usual, to high-quality research. Yet, there are important changes compared to the past. The traditional oral communications have been converted into topic symposia organized exclusively by the early-career pharmacology members. Furthermore, an effort has been made, whenever possible, to bring together basic and clinical content. Indeed, while a good researcher in any discipline is measured by the ability to answer relevant scientific questions and thus push the boundaries of knowledge, a pharmacologist has a further challenge: to move transversally across all areas of drug development, from target identification to market access dynamics, encompassing preclinical, non-clinical and clinical research, evidence generation and evaluation, as well as regulation and market dynamics.

The congress aims to be a showcase of the golden age we are experiencing. Drugs are being developed much more rapidly than in the past, a significantly greater number of drugs is being developed, and the available technologies have increased substantially. This new wealth is accompanied by increased complexity at every level and therefore by the need for significant changes. Proximity of care, system sustainability, telemedicine, translational medicine, precision medicine, prevention, and artificial intelligence are no longer slogans but are embedded in the pharmaceutical world we live in. In this context, the role of the pharmacologist is central, as the transversal nature of the profession will bring significant value to the system.

Finally, the congress will address many of the key cross-cutting themes at the heart of current discussions, from high-quality basic research to new tools in clinical research, from real-world evidence to regulatory uncertainties, from evidence-based medicine to the personalization of therapies, including gender pharmacology, and from economic sustainability to organizational innovation.

The congress will bring together leading experts from academia, the public and private sectors, thereby fostering a high-level and productive scientific environment. To support this process, structured networking opportunities will be provided for trainees, members serving on Ethics Committees, professionals working in Phase I Units and molecular tumor boards, and members of the SIF sections.

Tematiche:farmacologiadolore cronicomalattie metabolicheneuroscienzemalattie infiammatorie autoimmunifarmacologia di genere

Il programma dei quattro giorni

Giorno 1
Giorno 2
Giorno 3
Giorno 4
8:30
9:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
SY24 Pharmacological innovations for the management of metabolic disorders and their comorbidities
SY24 Pharmacological innovations for the management of metabolic disorders and their comorbidities
Targeting the liver-brain axis in diabesity-associated Alzheimer's disease: hepatic NLRP3 as a pharmacological nodeClaudio PirozziSy24
Impact of ANGPTL3-targeted therapies on lipids and apolipoproteins: a meta-analysis of randomized controlled trialsElena Olmastroni
Beyond the trip: the metabolic action of psilocybin in steatotic liver diseaseAnna Signor
Competing risk of death and neurological outcomes in elderly diabetic patients treated with GLP-1 receptor agonistsVera Battini
Effects of N-acylethanolamines on obesity-induced cardiometabolic alterationsFederica Comella
Pharmacological modulation of the paracannabinoid system in diet-induced overweight: insights into early cardiac dysfunctionAlessia Campagna
Cholinergic stimulation promotes resilience and PD-L1 expression in human terminally differentiated β-cells: implications for novel Type 1 Diabetes strategiesFrancesco Petragnano
Adolescent high-fat diet programs a lipotoxic and bioenergetically inefficient skeletal muscle phenotype: protective role of oleoylethanolamideChristian Sepe
SY01 From visceral to somatic pain: mechanisms, pathways, and therapeutic targets
SY01 From visceral to somatic pain: mechanisms, pathways, and therapeutic targets
μ-opioid receptor in NK cells as a potential biomarker for neuropathic pain: evidence from the CCI model and modulation by bergamot polyphenolic fractionLucia Carmela PassacatiniSy01
Decoding vulvodynia: from pelvic sensitivity to central pain processingMichela Perrone
Exploring the dual role of Mangifera indica L. in alleviating abdominal visceral pain and inflammationAnna Schettino
Dissecting the gut–vulva axis: translational insights from IBS-associated vulvodynia and evaluation of glucosinolates-based therapyElena Lucarini
From intestinal epithelium to visceral pain: molecular mechanisms involved in IBSSofia Faggin
Dissecting MOR-CB1 interactions in neuronal cell models: implications for opioid-cannabinoid co-treatment in chronic painGaia Lusoli
S5 Vulnerability to relapse: behavioral, circuit and molecular fingerprints
S5 Vulnerability to relapse: behavioral, circuit and molecular fingerprints
Cocaine withdrawal during adolescence alters hippocampal neuro-glia interaction dynamics and excitatory–inhibitory synapses in response to an acute stressLucia CaffinoS5
Impact of adolescent social exclusion on relapse susceptibility to alcohol seeking and stress-related behaviors in male and female ratsEsi Domi
Dorsal raphe projections to the central amygdala and nucleus accumbens drive methamphetamine relapseDaniele Caprioli
Multidimensional addiction profiling in outbred rats: from individual differences to medication developmentGiordano de Guglielmo
S24 Modelling and simulation as drivers of innovation in pharmacology
S24 Modelling and simulation as drivers of innovation in pharmacology
From data to modelOscar Della PasquaS24
From mechanistic knowledge to translational impact: a systems biology and QSP perspectiveEnrico Domenici
Regulatory impact of PK and PD modelling and simulation: expectations and practical casesSerena Zamponi
Novel approaches to HypoparathyroidismMaria Luisa Brandi
S18 Optimizing polypharmacy management in complex patients: key priorities, tools, and strategic approaches
S18 Optimizing polypharmacy management in complex patients: key priorities, tools, and strategic approaches
Medication reviews and pharmacogenetics: the critical role of data integrationValeria ContiS18
Medication review in different care settings, constraints and potential benefitsElisabetta Poluzzi
Artificial Intelligence in medication review and deprescribing servicesGianluca Trifirò
Clinical assessment of drug–drug interactions: insights from a national pilot studyRiccardo Giossi
AIFA's Position Paper on the implementation of precision medicineRobert Nisticò
S1 Chronic pain 2.0: emerging mechanisms and therapeutic strategies
S1 Chronic pain 2.0: emerging mechanisms and therapeutic strategies
Emerging strategies for pain management in Fabry Disease, a rare genetic disorderSilvia FranchiS1
Proteome-wide characterization of neuroinflammatory signatures in morphine-exposed spinal tissue: modulation by ultramicronized palmitoylethanolamideAlessandra Toti
Effect of conditioned diet in a model of early life-induced widespread pain: potential role of HCAR2 receptorsCarmela Belardo
Neuroinflammatory mechanisms in opioid-related side effectsLaura Rullo
NanoBEO: transdermal nanotechnology for the management of pain and agitation in severe dementiaDamiana Scuteri
SY25 Role of sex differences in the modulation of lipid-derived mediators across different pathological conditions
SY25 Role of sex differences in the modulation of lipid-derived mediators across different pathological conditions
Dysfunctional gut microbiota–endocannabinoid axis exacerbates skeletal muscle and brain deficits in Duchenne muscular dystrophy (DMD)Noemi Di MuragliaSy25
Sex-dependent modulation of audiogenic seizures by ketogenic diet in a GluN2A(N615S) model of GRIN-related encephalopathyAlessandra Lodi
Sex-specific lipid mediator profile drives pulmonary fibrosis pathogenesis in miceDanilo D'Avino
Sex-specific pharmacotherapy and vascular stiffness in hypertensionMarialuisa Sveva Marozzi
S14 Psychedelics and more: innovative treatments for neurodevelopmental diseases and therapeutic challenges
S14 Psychedelics and more: innovative treatments for neurodevelopmental diseases and therapeutic challenges
Sex dependent behavioral and brain molecular effects of psilocybin in mice exposed to early life stressLaura MusazziS14
Psilocybin in neurodevelopmental disorders: preclinical insights into mechanisms of actionViviana Trezza
Cortico-striatal pathophysiology for neurodevelopmental disorders associated with 16p11.2 CNVs: implications for therapeutic targetingIlaria Maria Morella
SHANK3 related autism: from cell biology to new treatment opportunitiesChiara Verpelli
S33 From maternal well-being to offspring mental health: molecular determinants of intergenerational vulnerability
S33 From maternal well-being to offspring mental health: molecular determinants of intergenerational vulnerability
Mechanistic insights into how gestational stress programs long-term vulnerabilityAlessia MarchesinS33
Examine the association between maternal cannabis use and sex-specific dysfunctional mitochondrial bioenergetics leading to dopamine-related psychopathological traits in the offspringFederico Brandalise
Maternal depression and psychosocial stress, before and during pregnancy, alter neurodevelopmental trajectories of the progeny by remodeling placental transcriptional and epigenetic landscapesJuliet Richetto
Demonstrate how post-parturition alcohol exposure disrupts neuroadaptations driven by motherhoodSebastiano Bariselli
Deciphering the role of IL-17A in ASD-like phenotypes: evidence from a maternal immune activation mouse modelAnna Maria Tartaglione
Sex-divergent effects of cannabidivarin treatment in rats prenatally exposed to VPAErica Zamberletti
S27 Therapeutic advances in developmental and epileptic encephalopathies: present and future
S27 Therapeutic advances in developmental and epileptic encephalopathies: present and future
From genotype-phenotype correlations to emerging therapeutic strategies in SCN1A-related neurological disordersPaola ImbriciS27
Gut Microbiota in Angelman Syndrome: toward biomarkers and novel therapeutic strategiesCarmen De Caro
Investigating sex differences in a validated model of GRIN2A-related DEE: psychopathological and therapeutic implicationsIlaria Bertocchi
Targeted therapies in KCNQ2-related developmental and epileptic encephalopathiesFrancesco Miceli
SY27 Environmental stress as a driver of neuro-immuno-metabolic disease: risk factors and vulnerability mechanisms
SY27 Environmental stress as a driver of neuro-immuno-metabolic disease: risk factors and vulnerability mechanisms
RACK1 modulation as a mechanistic platform for screening immunotoxic effects of endocrine disrupting chemicalsMirco MasiSy27
Environmental chemicals as drivers of neuronal vulnerability: glutamatergic receptor dynamics in critical developmental windowsMelania Maria Serafini
Nanoplastic co-exposure as an emerging environmental driver of metabolic dysfunction in liver and adipose tissueStefania Melini
Downregulation of Kv7 channels contributes to angiotensin-II induced modulation of neuronal activity in brain areas controlling sympathetic toneStefania Iervolino
Invisible invaders: subacute nanoplastic ingestion drives neuroinflammation via the gut-brain axisFederico Ciceri
Early life stress alters hypothalamic-peripheral metabolic signaling linking psychiatric and metabolic vulnerabilityIlari D'Aprile
S16 Biological therapies and molecular target drugs in chronic inflammatory autoimmune diseases: from basic and translational research to clinical evidence
S16 Biological therapies and molecular target drugs in chronic inflammatory autoimmune diseases: from basic and translational research to clinical evidence
A new frontier in IL-17 antagonism: FM15TM, a first-in-class linear small peptide with translational potential in chronic inflammation and autoimmune diseasesFrancesco MaioneS16
Reframing IMIDs: the IL-23 pathway from mechanisms to pharmacological perspectivesLuca Antonioli
Novel imaging-based methods for validating immunopharmacology in vivoIshii Masaru
Autoimmune diseases from a pharmacological perspective: mechanisms and clinical challengesAnnamaria Iagnocco

Dove si svolgerà

Il corso si tiene presso Centro Congressi Lingotti, Via Nizza, Torino.

Via Nizza, 280, Torino (TO)

Come ottieni 17 crediti

2Partecipa in aula

25-28 novembre 2026, a Torino

3Supera la verifica

Questionario a risposta multipla online

Responsabili e docenti

Provider

3P SOLUTION SRLID Provider N° 327 · Città: Milano (MI) · Tipologia: Società, Agenzie Ed Enti Privati · Stato accreditamento: Standard - 2° Rinnovo

Responsabile scientifico

  • Armando GenazzaniResponsabile scientifico
    Specializzazione
    Professore Universitario. Presidente Sif
    Responsabile scientifico

Relatori e docenti

  • Stefania Maria CerutiModeratore
  • Elena OlmastroniRelatore
  • Claudio PirozziRelatore

Domande frequenti

L'evento è accreditato per la mia professione e disciplina?

L'evento è accreditato per: Medico Chirurgo (Allergologia Ed Immunologia Clinica, Dermatologia E Venereologia, Medicina Fisica E Riabilitazione, Medicina Aeronautica E Spaziale, Psichiatria, Medicina Legale, Igiene, Epidemiologia E Sanità Pubblica, Medicina Dello Sport, Oftalmologia, Farmacologia E Tossicologia Clinica, Medicina Nucleare, Continuità Assistenziale); Chimico (Chimica); Medico Chirurgo (Gastroenterologia, Geriatria, Nefrologia, Neuropsichiatria Infantile, Chirurgia Maxillo-Facciale, Chirurgia Pediatrica, Neuroradiologia); Farmacista (Farmacista Pubblico Del Ssn); Medico Chirurgo (Direzione Medica Di Presidio Ospedaliero, Organizzazione Dei Servizi Sanitari Di Base, Medicina Subacquea E Iperbarica, Medicina Termale, Oncologia, Pediatria, Chirurgia Vascolare, Ginecologia E Ostetricia, Otorinolaringoiatria, Neurofisiopatologia); Biologo (Biologo); Medico Chirurgo (Cure Palliative, Epidemiologia, Endocrinologia, Malattie Infettive, Microbiologia E Virologia, Igiene Degli Alimenti E Della Nutrizione, Audiologia E Foniatria); Tecnico Sanitario Laboratorio Biomedico (Iscritto Nell’Elenco Speciale Ad Esaurimento); Medico Chirurgo (Angiologia, Genetica Medica, Malattie Dell'apparato Respiratorio, Neurologia, Cardiochirurgia, Chirurgia Toracica, Patologia Clinica (Laboratorio Di Analisi Chimico-Cliniche E Microbiologia), Pediatria (Pediatri Di Libera Scelta), Scienza Dell'alimentazione E Dietetica); Farmacista (Farmacista Di Altro Settore); Medico Chirurgo (Cardiologia, Medicina Interna, Neonatologia, Reumatologia, Chirurgia Generale, Neurochirurgia, Anestesia E Rianimazione, Biochimica Clinica, Laboratorio Di Genetica Medica, Medicina Trasfusionale, Radiodiagnostica, Medicina Generale (Medici Di Famiglia)); Farmacista (Farmacista Territoriale); Medico Chirurgo (Psicoterapia, Medicina Di Comunità E Delle Cure Primarie, Ematologia, Malattie Metaboliche E Diabetologia, Medicina D'emergenza-Urgenza, Radioterapia, Chirurgia Plastica E Ricostruttiva, Ortopedia E Traumatologia, Urologia, Anatomia Patologica, Medicina Del Lavoro E Sicurezza Degli Ambienti Di Lavoro); Assistente Sanitario (Assistente Sanitario); Tecnico Sanitario Laboratorio Biomedico (Tecnico Sanitario Laboratorio Biomedico).

Quanti crediti ECM ottengo e come arrivano su Co.Ge.A.P.S.?

«43° National Congress Of The Italian Society Of Pharmacology…» assegna 17 crediti ECM al superamento della verifica di apprendimento. I crediti vengono inviati dal provider "3P Solution Srl" al tuo account Co.Ge.A.P.S. dopo la conclusione del corso.

Si svolge online o in presenza?

In presenza: «43° National Congress Of The Italian Society Of Pharmacology…» si tiene a Via Nizza, Torino.

Quanti partecipanti sono previsti per l'evento?

Per «43° National Congress Of The Italian Society Of Pharmacology…» sono previsti fino a 80 partecipanti.

Quanto pesa questo corso sull'obbligo del triennio 2026-2028?

Con 17 crediti, «43° National Congress Of The Italian Society Of Pharmacology…» copre l'11,3% dei 150 crediti richiesti nel triennio. Con l'esonero o la riduzione per chi ha completato il triennio precedente la quota sale.

A quale obiettivo formativo corrisponde questo evento?

«43° National Congress Of The Italian Society Of Pharmacology…» ha come obiettivo formativo "Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere", parte degli "Obiettivi formativi tecnico-professionali".

Quali competenze si acquisiranno durante l'evento?

Al termine di «43° National Congress Of The Italian Society Of Pharmacology…»:

Il congresso nazionale della società italiana di farmacologia rappresenta il principale momento di aggiornamento scientifico della disciplina a livello nazionale e si propone di approfondire le più recenti acquisizioni in ambito farmacologico. il programma copre numerose aree della farmacologia, dalla ricerca di base alla farmacologia clinica, includendo farmacovigilanza, farmacoepidemiologia, farmacogenetica, medicina personalizzata e malattie rare. attraverso la presentazione e discussione di evidenze scientifiche, nuove tecnologie e tematiche di elevata specializzazione, l'evento consentirà ai partecipanti di acquisire e aggiornare competenze tecnico-professionali specifiche delle diverse aree della farmacologia e delle discipline correlate

Si tratta di un evento residenziale interattivo?

No, «43° National Congress Of The Italian Society Of Pharmacology…» non è un evento residenziale interattivo.

Quali metodi di insegnamento sono utilizzati nell'evento?

In «43° National Congress Of The Italian Society Of Pharmacology…» i metodi didattici previsti sono: lezioni magistrali e serie di relazioni su tema preordinato.

L'evento si terrà in italiano?

No, «43° National Congress Of The Italian Society Of Pharmacology…» non si terrà esclusivamente in italiano.

Come funziona la verifica di presenza?

In «43° National Congress Of The Italian Society Of Pharmacology…» la presenza viene verificata tramite firma di presenza.

Come funziona la verifica di apprendimento?

In «43° National Congress Of The Italian Society Of Pharmacology…» la verifica dell'apprendimento avviene tramite questionario a risposta multipla online.

Posso sommare più corsi di 3P Solution Srl?

Sì: oltre a «43° National Congress Of The Italian Society Of Pharmacology…» puoi seguire tutti i corsi che vuoi di 3P Solution Srl, non c'è un limite per provider.

Altri corsi ECM simili a questo

BlendedLt3 Srl

Cardioacademy 2026 innovazione in cardiologia in scenari clinici complessi

Evento Blended di Lt3 Srl a Milano con obiettivo "Obiettivi formativi tecnico-professionali"

25 crediti ECM · 26 maggio - 20 ottobre 2026GratuitoScopri →
FSCDialecticon Srl

Artropatia psoriasica & microbiota intestinale

Progetto FSC (7 crediti) su artrite psoriasica e microbiota intestinale, rivolto a reumatologi e gastroenterologi. Strutturato in kick-off meeting, midterm con analisi di casi clinici individuali e closing meeting, con focus su asse intestino-articolazioni, IL-23 e terapie biotecnologiche.

22 crediti ECM · 8 settembre - 20 ottobre 2026GratuitoScopri →
FSCHealth Meetings Group Srl

Malattie infiammatorie croniche intestinali, focus sul paziente di interesse multidisciplinare: Corso ospedaliero teorico-pratico

Evento FSC di Health Meetings Group Srl a Milano con obiettivo "Obiettivi formativi tecnico-professionali"

18 crediti ECM · 21 - 22 ottobre 2026GratuitoScopri →
RESCentro Cardiologico Monzino, Irccs

ACLS - Supporto vitale cardiovascolare avanzato

Evento RES di Centro Cardiologico Monzino, Irccs a Milano con obiettivo "Obiettivi formativi tecnico-professionali"

17,8 crediti ECM · 21 - 22 ottobre 2026GratuitoScopri →
FSCAboutevents Srl

Psoriasi e rischio articolare: Percorsi di identificazione precoce e personalizzazione terapeutica

Evento FSC di Aboutevents Srl a Milano con obiettivo "Obiettivi formativi tecnico-professionali"

16 crediti ECM · 11 maggio - 21 ottobre 2026GratuitoScopri →
RESMgm Congress

Advanced training in kidney stone surgery

Evento RES di Mgm Congress a Bari con obiettivo "Obiettivi formativi tecnico-professionali"

13,5 crediti ECM · 20 - 21 ottobre 2026GratuitoScopri →

Sei un provider ECM?

Contattaci per scoprire come possiamo collaborare.

Contattaci